ABT-494
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Background: Upadacitinib (UPA, ABT-494) is a selective, oral JAK-1 inhibitor studied in two phase 2 randomized controlled trials…
Background In patients (pts) with rheumatoid arthritis (RA) treated with ABT-494, dose-dependent increases in levels of low and…
Background Tocilizumab (TCZ), a humanized interleukin-6 receptor inhibitor, has been shown effective in suppressing symptoms of…
Background ABT-494 is a selective Janus Kinase 1 inhibitor. In two Phase 2b studies in subjects with rheumatoid arthritis, 6 mg…
Background ABT-494 is a selective Janus Kinase 1 inhibitor currently being evaluated in Phase 3 trials for treatment of…
Background ABT-494 is a novel selective JAK1 inhibitor. Objectives The safety, efficacy, and dose response of ABT-494 were…
Background ABT-494 is a novel selective JAK1 inhibitor. Objectives The safety and efficacy of ABT-494 was characterized vs…
Background ABT-494 is a Janus activated kinase (JAK) inhibitor that demonstrated robust efficacy in Phase 2 clinical trials in…
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by synovial inflammation and joint destruction…